Atrasentan
- Generic Name
- Atrasentan
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C29H38N2O6
- CAS Number
- 173937-91-2
- Unique Ingredient Identifier
- V6D7VK2215
- Background
Atrasentan is a substance that is being studied in the treatment of cancer. It belongs to the family of drugs called endothelin-1 protein receptor antagonists. It is a novel, selective endothelin A receptor antagonist (SERA).
- Indication
Investigated for use/treatment in prostate cancer and cancer/tumors (unspecified).
- Associated Conditions
- -
- Associated Therapies
- -
Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure
- Conditions
- First Posted Date
- 2002-06-04
- Last Posted Date
- 2006-08-15
- Lead Sponsor
- Abbott
- Target Recruit Count
- 200
- Registration Number
- NCT00038662
- Locations
- ๐บ๐ธ
Carolinas Medical Centre, Charlotte,, North Carolina, United States
๐บ๐ธUrologic Specialists Of Oklahoma, Inc., Tulsa,, Oklahoma, United States
๐บ๐ธCenter for Urologic Care, West Reading, Pennsylvania, United States
A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer
- Conditions
- First Posted Date
- 2002-05-13
- Last Posted Date
- 2006-08-15
- Lead Sponsor
- Abbott
- Target Recruit Count
- 1000
- Registration Number
- NCT00036543
- Locations
- ๐จ๐ฆ
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
๐บ๐ธAlaska Clinical Research Center, LLC, Anchorage, Alaska, United States
๐บ๐ธClinical Physiology Associates, Fort Myers, Florida, United States
Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer
- Conditions
- First Posted Date
- 2002-05-13
- Last Posted Date
- 2007-08-15
- Lead Sponsor
- Abbott
- Target Recruit Count
- 941
- Registration Number
- NCT00036556
- Locations
- ๐บ๐ธ
Ntouch Research Corporation, Dallas, Texas, United States
๐จ๐ฆPrincess Margaret Hospital, Toronto, Ontario, Canada
๐บ๐ธUCLA School of Medicine, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.